Share on LinkedInShare on LinkedIn

ARTICLE · 26 JUNE 2020

Regeneron Patents Revoked For Claim Breadth

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

The UK Supreme Court has now issued its judgement in the long running Regeneron v Kymab transgenic mouse cases, finding the Regeneron patents invalid for lack of sufficiency.

European UnionIntellectual Property

The UK Supreme Court has now issued its judgement in the long running Regeneron v Kymab transgenic mouse cases, finding the Regeneron patents invalid for lack of sufficiency.  

Regeneron Pharmaceuticals Inc sued Kymab Ltd for infringement of their transgenic mouse patents (EP1360287 and EP2264163). The mice covered by the Regeneron patents included a combination of mouse and human DNA, meaning that they produced antibodies that can be used in the treatment of human illnesses without causing immunological sickness in a mouse. The Kymab mice (Kymice) have a similar genetic structure to the Regeneron mice. Kymab's defence against their alleged infringement was that the Regeneron patents were invalid for lacking sufficiency.  

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from